| M0001 |
Advancing cancer care mvp |
Advancing cancer care mips value pathways |
| M0002 |
Opt care kidney hlth mvp |
Optimal care for kidney health mips value pathways |
| M0003 |
Opt care episod neuro mvp |
Optimal care for patients with episodic neurological conditions mips value pathways |
| M0004 |
Support care neur cond mvp |
Supportive care for neurodegenerative conditions mips value pathways |
| M0005 |
Value in primary care mvp |
Value in primary care mips value pathway |
| M0010 |
Eom meos payment |
Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services |
| M0064 |
Visit for drug monitoring |
Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders |
| M0075 |
Cellular therapy |
Cellular therapy |
| M0076 |
Prolotherapy |
Prolotherapy |
| M0100 |
Intragastric hypothermia |
Intragastric hypothermia using gastric freezing |
| M0201 |
Pne flu hepb cov home admin |
Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home |
| M0220 |
Tixagev and cilgav inj |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
| M0221 |
Tixagev and cilgav inj hm |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0222 |
Bebtelovimab injection |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
| M0223 |
Bebtelovimab injection home |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0224 |
Pemivibart infusion |
Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, includes infusion and post administration monitoring |
| M0239 |
Bamlanivimab-xxxx infusion |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
| M0240 |
Casiri and imdev repeat |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
| M0241 |
Casiri and imdev repeat hm |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses |
| M0243 |
Casirivi and imdevi inj |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
| M0244 |
Casirivi and imdevi inj hm |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0245 |
Bamlan and etesev infusion |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
| M0246 |
Bamlan and etesev infus home |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency |
| M0247 |
Sotrovimab infusion |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
| M0248 |
Sotrovimab inf, home admin |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0249 |
Adm tocilizu covid-19 1st |
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose |
| M0250 |
Adm tocilizu covid-19 2nd |
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose |
| M0300 |
Iv chelationtherapy |
Iv chelation therapy (chemical endarterectomy) |
| M0301 |
Fabric wrapping of aneurysm |
Fabric wrapping of abdominal aneurysm |
